Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


1,2,5-thiadiazoles (including hydrogenated)

Subclass of:

514 - Drug, bio-affecting and body treating compositions

514001000 - DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)

514183000 - Heterocyclic carbon compounds containing a hetero ring having chalcogen (i.e., O,S,Se or Te) or nitrogen as the only ring hetero atoms DOAI

514359000 - Five-membered hetero ring containing at least one nitrogen ring atom (e.g., 1,2,3-triazoles, etc.)

514361000 - Plural ring nitrogens and a single chalcogen in the hetero ring

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
514362000 1,2,5-thiadiazoles (including hydrogenated) 13
200802937821,1,3-Trioxo-1,2,5-Thiadiazolidines and Their Use as Ptp-Ases Inhibitors - Compounds of the formula11-27-2008
20110269804INSECTICIDAL COMPOUNDS - A compound of formula (I):11-03-2011
20120108643METHOD OF INCREASING THE EXTENT OF ABSORPTION OF TIZANIDINE - An article and method for increasing the extent of tizanidine absorption in a patient receiving tizanidine therapy. Tizanidine may be administered in the form of an immediate release tablet composition at or around the time food is consumed. The composition may be packaged in a container for distribution.05-03-2012
20120196906Substituted Imidazole Derivatives, Compositions, and Methods of Use as PTPase Inhibitors - The present invention provides imidazole derivatives of Formula (I-IV), methods of their preparation, pharmaceutical compositions comprising the compounds of Formula (I-IV), and their use in treating human or animal disorders. The compounds of the invention inhibit protein tyrosine phosphatase 1B and thus can be useful for the management, treatment, control, or the adjunct treatment of diseases mediated by PTPase activity. Such diseases include Type I diabetes and Type II diabetes.08-02-2012
20090062354Method of increasing the extent of absorption of tizanidine - An article and method for increasing the extent of tizanidine absorption in a patient receiving tizanidine therapy. Tizanidine may be administered in the form of an immediate release tablet composition at or around the time food is consumed. The composition may be packaged in a container for distribution.03-05-2009
20080262050Organic Compounds - Compounds of the formula10-23-2008
201000359421-orthofluorophenyl substituted 1,2,5-thiazolidinedione derivatives as ptp-as inhibitors - Compounds of the formula02-11-2010
20090170911NOVEL AZOLE COMPOUND - Azole compounds represented by formula I:07-02-2009
201100925541,3,5 TRI-SUBTITUTED BENZENES FOR TREATMENT OF ALZHEIMER'S DISEASE AND OTHER DISORDERS - The present disclosure relates to novel 1,3,5 tri-substituted benzenes of general formula (I), (II) or (III) and the use of such compounds in the treatment of diseases associated with the deposition of -amyloid in the brain.04-21-2011
20080214629CONTROLLED RELEASE COMPOSITIONS OF TIZANIDINE - The present invention relates to a novel controlled release formulations of tizanidine. The invention also provides methods of using novel controlled release formulations of tizanidine to treat a patient.09-04-2008
20100130566Treatment of autism spectrum disorders with agents that activate the Locus Coeruleus - Noradrenergic system - Methods are provided for treating autism spectrum disorders (ASD) using agents that activate the locus coeruleus-noradrenergic (LC-NA) system of the brain and for screening for compounds for treating ASD comprising determining whether or not the compounds activate the LC-NA system.05-27-2010
20080207703Antibacterial heterocyclic ureas - The present invention provides novel heterocyclic urea compounds having useful antibacterial activity, pharmaceutical compositions comprising one or more of these compounds, methods of making the same, and methods of using the same.08-28-2008
20110160253DEUTERATED TIZANIDINE - This disclosure relates to novel benzothiadiazoles, their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an α06-30-2011

Patent applications in class 1,2,5-thiadiazoles (including hydrogenated)